Walk into any pharmaceutical manufacturing facility and ask the quality team about FDA inspections. There’s a good chance process validation comes up—and not in a good way.
The numbers tell the story. In fiscal year 2025, FDA issued 713 Form 483s to drug manufacturers. Section 211.100(a)—which covers written production and process control procedures—showed up 162 times. That’s 5.7% of all drug-related citations, making it the third most cited section. Add in the related 211.110(a), and you’re looking at nearly 200 citations in a single year.
2024 was worse. That year, 211.100(a) topped the list entirely.
Here’s what really gets me: this isn’t new. Data spanning 2006 to 2022 shows process validation consistently ranking in the top six observations. And if you’re counting warning letters, the kind that precede actual enforcement action, 26% of FDA warning letters issued between 2010 and 2020 cited process validation deficiencies. One in every four.
So why does this keep happening?
The 2011 Shift Nobody Fully Made
In 2011, FDA published a guidance document that reframed how the industry should think about process validation. The old model was straightforward: run three commercial-scale batches, get a passing report, file it away. Done.
The new model added a third stage that changed everything: Continued Process Verification, or CPV.
What FDA wanted was a lifecycle approach. Stage 1 covered Process Design—figuring out what you were trying to do and why. Stage 2 was Process Performance Qualification, the traditional three batches, but with a different purpose. Stage 3 was CPV: continuous monitoring, statistical process control, trend analysis, all throughout commercial production.
The problem is that many companies never made the mental switch. They still treat validation as the three-batch exercise it was before 2011. The documents get filed. The report gets completed. And then nothing. No ongoing monitoring. No real-time data analysis. No systematic look at whether the process is still behaving the way it should.
When inspectors show up and ask where the CPV data is, where the trend reports are, where the ongoing monitoring plan is, these companies have nothing to show. The validation report exists, but it’s a snapshot, not a story.
“We Have a Procedure” Isn’t Enough Anymore
FDA’s expectations have shifted in another way that catches companies off guard.
For years, if you had a written procedure, you were fine. Inspectors checked for existence and basic compliance. But FDA has moved past that. Now they want to know why your procedure looks the way it does. What’s the scientific justification?
Inspectors ask harder questions now. How did you identify your critical process parameters? Was that based on development data, or did someone pick numbers that felt reasonable? Is your sampling plan statistically sound? Does your PPQ batch actually represent worst-case commercial conditions? Are your acceptance criteria backed by data, or did you copy them from the specification sheet?
One pattern shows up repeatedly in warning letters: companies trying to use final product release results to prove their process works. The logic seems sound on the surface. If the product passes all its tests, the process must be good, right?
Wrong. That’s missing the point entirely.
Process validation isn’t about proving any individual batch is acceptable. It’s about proving the process system is capable of consistently producing acceptable product. A passing batch tells you that batch passed. It doesn’t tell you the process is fundamentally sound, stable, that it will keep performing tomorrow and next month and a year from now.
When validation documentation lacks scientific rigor, when critical parameters aren’t properly justified, when sampling plans don’t hold up to statistical scrutiny, when PPQ batches don’t reflect real production variability—deficiencies are inevitable.
The Third Stage Nobody Does Right
CPV is the most misunderstood piece of the 2011 framework.
The theory goes like this: once your process is validated, you keep watching it. You collect data throughout commercial production. You use statistical tools to spot trends. You catch problems before they become big problems. You feed what you learn back into the validation lifecycle.
What actually happens at many companies: CPV becomes the annual quality review. Someone pulls together some data once a year, makes a few charts, writes a paragraph saying “process remains validated,” and moves on.
FDA has been clear this doesn’t cut it. A 2024 warning letter illustrated the gap perfectly. The company had procedures requiring SPC monitoring. During the inspection, FDA asked to see the SPC data. The company admitted it hadn’t actually been running SPC analysis. Not because the procedure was wrong. Because nobody was doing it.
When FDA made them run the analysis retroactively, four negative trends showed up immediately. Trends that had been hiding in plain sight. Trends that would have been caught months or years earlier if CPV had been running as designed.
This is what happens when CPV becomes a paperwork exercise instead of a living system.
It’s Never Just About Validation
Here’s something that often gets missed: the validation failures aren’t isolated incidents. They cluster with other quality system failures in ways that reveal deeper problems.
Look at the 2025 Form 483 rankings. The top three observations form a constellation: 211.22(d) (quality unit responsibilities), 211.192 (deviation investigations), and 211.100(a) (process control procedures).
These aren’t coincidentally grouped. They’re symptoms of the same underlying issue.
A quality unit that isn’t fully exercising its oversight responsibilities can’t drive rigorous process validation. A deviation investigation system that doesn’t dig deep enough means abnormal signals from the process never get properly analyzed. And a process validation system that doesn’t monitor ongoing performance generates a steady stream of deviations that the broken investigation system can’t keep up with.
Process validation problems are usually process validation system problems. And the system lives inside a quality organization that isn’t functioning as it should.
New Technologies, Same Old Struggles
The landscape isn’t getting simpler. If anything, the pressure is mounting.
Cell and gene therapy products have unique manufacturing challenges that don’t fit neatly into traditional validation frameworks. In January 2026, FDA issued guidance acknowledging this, allowing more flexibility in validation approaches, including dropping the mandatory three-batch PPQ requirement under certain conditions. On one hand, this reflects scientific maturity. On the other hand, it puts more burden on manufacturers to justify their approaches. Instead of following a well-trodden path, companies need deeper process understanding and stronger scientific arguments.
The same pattern shows up in 3D printed pharmaceuticals. EMA released GMP guidance in March 2026 specifically addressing printing processes and validation requirements. PDA’s revised Technical Report 60 encourages enhanced approaches like continuous process verification.
The message from regulators is consistent: they expect more science, more understanding, more sophistication, not less.
So What Actually Works?
I’ve seen companies break this cycle. It usually comes down to three shifts.
First, treat validation as knowledge management, not paperwork. The point of process validation isn’t to produce a binder full of documents. It’s to understand your process well enough that you can trust it. When teams approach validation this way, when they’re trying to learn something rather than just check a box, the quality of the work changes completely.
Second, make CPV operational, not annual. SPC tools aren’t complicated. The challenge is embedding them into daily operations so data gets collected, analyzed, and acted upon continuously. If your process monitoring only happens once a year, it’s not working.
Third, give quality the authority it needs. Process validation requires cross-functional effort, but someone has to own it and drive it. When quality units lack the resources or authority to enforce standards, the whole system suffers.
The uncomfortable truth is that process validation keeps failing because it reflects how companies actually manage quality, not just their documentation practices. The validation report is a mirror. It shows what’s really going on.
And that’s exactly why it keeps showing up in inspections.
FAQ Section
Why does process validation consistently rank as a top FDA inspection finding?
Process validation remains a top inspection finding because the industry has been slow to fully adopt FDA’s 2011 lifecycle approach. Many companies still treat validation as a one-time event (three batches, then done) rather than an ongoing process that spans the entire product lifecycle. The shift from checking boxes to genuinely understanding and monitoring your process hasn’t happened everywhere yet.
What’s the difference between PPQ and CPV in FDA process validation?
PPQ (Process Performance Qualification) is Stage 2 of the validation lifecycle—the traditional three-batch qualification at or near commercial scale. CPV (Continued Process Verification) is Stage 3, the ongoing monitoring that happens throughout commercial production. Companies often do PPQ well but struggle with CPV, treating it as a once-a-year review rather than continuous surveillance.
How does FDA define adequate process validation today?
FDA expects process validation to follow a lifecycle approach with three stages: Process Design (Stage 1), Process Performance Qualification or PPQ (Stage 2), and Continued Process Verification or CPV (Stage 3). The critical shift is that validation doesn’t end after PPQ batches. Companies must continuously monitor their processes, use statistical tools, analyze trends, and demonstrate ongoing control throughout commercial manufacturing.
What are critical process parameters and why do they matter?
Critical Process Parameters (CPPs) are process variables that directly affect product quality. FDA expects companies to identify CPPs based on scientific development data, not guesswork. Your validation documentation should explain how each CPP was established, what its acceptable range is, and how it was challenged during qualification.
Can product release testing substitute for process validation?
No. This is a common misconception that FDA regularly addresses in warning letters. Product testing tells you whether a specific batch passes specification. Process validation proves your manufacturing system is capable of consistently producing acceptable product. Using release testing to justify process validity misses the point entirely—you need both, but they’re not interchangeable.
What happens during an FDA inspection when CPV is inadequate?
Inspectors will ask for your ongoing monitoring data, trend analyses, and statistical process control records. If you can’t demonstrate that CPV is actually running, or if your monitoring consists only of annual reports that aren’t acted upon, you’ll likely receive a Form 483 observation. In more serious cases, this can escalate to warning letters, especially if the gap between your procedures and actual practice is significant.
How does process validation tie into overall quality systems?
Process validation doesn’t exist in isolation. The top FDA inspection findings often cluster together: quality unit responsibilities, deviation investigations, and process control procedures. Weakness in one area tends to create problems in others. A quality organization that isn’t fully functional will struggle to maintain rigorous process validation, and process validation failures tend to generate deviations that broken investigation systems can’t properly address.
How are emerging technologies like CGT and 3D printing affecting process validation requirements?
Regulators are adapting. FDA’s January 2026 guidance for cell and gene therapy allows more flexibility, including dropping mandatory three-batch PPQ under certain conditions. But this flexibility comes with higher expectations for scientific justification. Manufacturers need deeper process understanding and stronger arguments for their approaches. EMA’s 3D printing guidance similarly requires rigorous validation. The trend is toward more science, not less.

Comments are closed